Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04509193 · ClinicalTrials.gov registry record
A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 116,049
- Enrollment target
NCT04509193 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 116,049 participants.
The verdict
NCT04509193 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 116,049 participants
- Enrollment target
Study Summary
In people with type 2 diabetes, the body does not make enough of a hormone called insulin or does not use insulin well. This results in high blood sugar levels. People with diabetes are more likely to have non-valvular atrial fibrillation (NVAF) compared to people who do not have diabetes. Having both NVAF and diabetes can increase the chances of developing other serious health conditions, like blood clots and strokes. People with NVAF may receive treatments to help lower the risk of blood clots. This can then help to lower the risk of having a stroke. Two of these treatments are rivaroxaban and warfarin. In this study, the researchers will look at how well rivaroxaban works and how safe it is compared to warfarin in routine clinical practice. The study will include men and women who are at least age 18 and who have NVAF and type 2 diabetes. The researchers in this study will use the participants' health information from an electronic database.
Interventions
- DRUG Warfarin
- DRUG Rivaroxaban (Xarelto, BAY59-7939)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116,049 participants |
| Start Date | 2020-08-21 |
| Est. Completion | 2021-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04509193
The ClinicalTrials.gov registry entry for NCT04509193 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 116,049 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Warfarin is the first listed.
NCT04509193 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04509193 about?
NCT04509193 is a clinical study titled "A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes". In people with type 2 diabetes, the body does not make enough of a hormone called insulin or does not use insulin well. This results in high blood sugar levels. People with diabetes are more likely to have non-valvular atrial fibrillation (NVAF) compared to people who do not have diabetes. Having b...
What is the current status of trial NCT04509193?
This trial is currently completed. The enrollment target is 116,049 participants. The study started on 2020-08-21. Estimated completion is 2021-07-31.
What interventions are being tested in trial NCT04509193?
The interventions under investigation include: Warfarin (DRUG), Rivaroxaban (Xarelto, BAY59-7939) (DRUG).
Who is sponsoring clinical trial NCT04509193?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.